Soligenix announces expansion of sgx302 (synthetic hypericin) phase 2a study in mild-to-moderate psoriasis

Clear biological signal demonstrated; additional patients to be enrolled princeton, n.j. , july 11, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the expansion of its phase 2a trial of sgx302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis after demonstration of biological effect in the initial five subjects.
SNGX Ratings Summary
SNGX Quant Ranking